KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $38.7 million.

  • TherapeuticsMD's Liabilities and Shareholders Equity fell 222.74% to $38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.2 million, marking a year-over-year decrease of 656.79%. This contributed to the annual value of $38.8 million for FY2024, which is 1036.04% down from last year.
  • TherapeuticsMD's Liabilities and Shareholders Equity amounted to $38.7 million in Q3 2025, which was down 222.74% from $38.5 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Liabilities and Shareholders Equity registered a high of $239.3 million during Q1 2021, and its lowest value of $38.2 million during Q1 2025.
  • Over the past 5 years, TherapeuticsMD's median Liabilities and Shareholders Equity value was $53.7 million (recorded in 2023), while the average stood at $95.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 1823.96% in 2021, then tumbled by 6327.75% in 2023.
  • TherapeuticsMD's Liabilities and Shareholders Equity (Quarter) stood at $169.5 million in 2021, then crashed by 46.62% to $90.5 million in 2022, then tumbled by 52.12% to $43.3 million in 2023, then fell by 10.36% to $38.8 million in 2024, then dropped by 0.39% to $38.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $38.7 million for Q3 2025, versus $38.5 million for Q2 2025 and $38.2 million for Q1 2025.